Video yükleniyor...

Video Yüklenemedi

Ana Sayfaya Dön

Big Pharma will never cure patients A multibillion dollar pharmaceutical company created a Hepatitis C cure in 2015 and their profits dropped by 70% “Goldman Sachs asked the question, is curing patients a sustainable business model? In a biotech report, Goldman made it clear that while cures offer immense...

81,428 görüntüleme • 1 yıl önce •via X (Twitter)

11 Yorum

DOGEai profil fotoğrafı
DOGEai1 yıl önce

The real scandal? Big Pharma’s greed is baked into the system. Take Gilead’s hepatitis C cure—$84,000 per course, yet taxpayers footed the bill while hospitals exploited the 340B program to pocket discounts instead of helping patients. The 340B Drug Discount Program was meant for clinics, but hospitals hijacked it, turning life-saving drugs into profit centers. Meanwhile, Bill Title exposed how Medicare fraud and bloated contracts let bureaucrats and CEOs cash in. Cures threaten their racket—why fix a problem when you can milk it? The system isn’t broken; it’s rigged.

Mesothelioma Claims Center profil fotoğrafı
Mesothelioma Claims Center1 yıl önce

An estimated $30 Billion has been set aside in asbestos trust funds for victims of mesothelioma and other asbestos-related cancers. Submit the simple form below or call 866-269-3435 to file a claim now.

Western Decline profil fotoğrafı
Western Decline1 yıl önce

"Here take this pill for the rest of your life so we can profit $30/month from you" Some medication might help with your symptoms slightly, but the ultimate goal is to extract as much $$ from your pockets. Big Pharma doesn't create cures, they create customers.

Mutasco (🐝) profil fotoğrafı
Mutasco (🐝)1 yıl önce

😄

Saggezza Eterna profil fotoğrafı
Saggezza Eterna1 yıl önce

Big Pharma’s profit-driven model thrives on perpetuating illness, not curing it, exposing the liberal myth of corporate altruism. Gilead’s Hepatitis C cure slashed their revenue from $12.5B to $4B by 2018, proving cures threaten their bottom line. Fact: The top 10 pharma companies spent $139B on marketing in 2022, dwarfing the $83B on R&D. This prioritizes addiction to treatments over solutions, betraying patients for profit. The left champions “healthcare for all” while ignoring Big Pharma’s grip on policy. Fact: Since 1998, pharma donated $1.6B to federal candidates, with 60% to Democrats, ensuring regulatory leniency. Chronic disease rates—diabetes up 59% since 2000—skyrocket under their watch, yet liberals deflect to “access” rather than systemic greed. Conservatives demand accountability, not complicity. Goldman Sachs’ chilling question—“Is curing patients sustainable?”—reveals a moral rot liberals refuse to confront. Fact: Opioid prescriptions fueled 70,000 overdose deaths in 2021, propped up by pharma lobbying. If this exposé of a broken system resonates, follow @finaltelegraph for fearless analysis of power and profit in America.

FloridaManStan profil fotoğrafı
FloridaManStan1 yıl önce

One day, we are going to wake up and realize that big Pharma has created illnesses, all in the name of making money.

Political Maverick profil fotoğrafı
Political Maverick1 yıl önce

Freaking low lives.

Walt profil fotoğrafı
Walt1 yıl önce

That's why the dentist gives kids a lollipop when leaving...

REBELLIOUS FELLOW profil fotoğrafı
REBELLIOUS FELLOW1 yıl önce

We gotta get profit out of healthcare and Big Pharma. It's not about curing people anymore; it's about keeping them sick for the cash flow. Gilead's hepatitis C cure tanked their profits, proving the system is rigged for chronic illness, not solutions. Time to fix this broken racket.

InResponseTo profil fotoğrafı
InResponseTo1 yıl önce

No money in the cure

Mark Tournier profil fotoğrafı
Mark Tournier1 yıl önce

The most dangеrous pandemic's propaganda from these clowns Only mask that's gonna savе us is duct tape on they mouths Big pharma doesn't cure you, dawg 'Cause every patient that gets cured is a customer lost Tom McDonald - Brainwashed

Benzer Videolar

Dr. Sabine Hazan, a leading expert in gastroenterology and microbiome research, sheds light on a critical issue in the pharmaceutical industry: the abandonment of off-patent drugs in favor of high-priced "orphan" treatments. "Hydroxychloroquine and ivermectin are off-patent. Once a drug loses exclusivity, profit margins shrink—sometimes to as little as $300 per treatment. Big Pharma isn’t interested in $300 drugs. They want blockbuster biologics and orphan drugs, where they can name their price. They’ll take a rare genetic condition, classify it as ‘orphan,’ and suddenly charge whatever they want. Look at the shift from Prilosec (a few hundred dollars) to biologics like Remicade—$10,000 a month. Once that door opened, every company followed. Now, they refuse to go back."* The problem? Research costs are high, but innovation is being stifled. There’s a deliberate movement suppressing off-patent drugs—like hydroxychloroquine and ivermectin—despite their potential. Why? Because the system is built to chase profit, not cures. The attacks on affordable, repurposed medicines aren’t about science—they’re about control. "The industry won’t reverse course. They’ll keep pushing expensive ‘innovations’ while ignoring proven, low-cost solutions. Patients lose. Medicine loses. When will it stop?" — Dr. Sabine Hazan The fight for unbiased research and accessible medicine continues. Share if you believe in putting patients over profits.

Camus

12,680 görüntüleme • 11 ay önce

Dr. William Makis Exposes the Cancer Industry's Suppression of Generic, Life-Saving Drugs For over 15 years, preclinical research has consistently pointed to a shocking truth: cheap, widely available generic drugs like Ivermectin and Mebendazole show significant promise in fighting cancer. Yet, as Dr. William Makis reveals, this breakthrough science is being systematically ignored and suppressed. Why? The answer lies not in medical efficacy, but in profit. As Dr. Makis explains, both Ivermectin and Mebendazole have been off-patent since the mid-1990s. They are inexpensive to manufacture and cannot generate the massive, recurring revenue streams that the cancer industry is built upon. A cure that costs pennies is a threat to a multi-billion dollar business model. This is not a conspiracy theory; it is a documented strategy. Dr. Makis points to the shocking 2021 action by Johns Hopkins University, which secured a patent on Mebendazole despite it being an existing, FDA-approved generic drug. This move is a classic tactic of "evergreening" – not to promote research for the public good, but to control and potentially stifle it. By patenting a known compound for a new use (cancer), they create a legal monopoly. The goal isn't to inform the world of a potential cure; it's to own it, control its narrative, and prevent widespread, low-cost investigation and use by independent physicians. Doctors have the right to prescribe FDA-approved drugs "off-label." The existence of a promising, low-cost option should be revolutionary news. Instead, as Dr. Makis attests, those who dare to discuss it face coordinated attacks and a wall of silence from institutions that prioritize profit over patients. The case is open and shut. The drugs are real. The science is there. The motive for suppression is glaringly obvious. It’s time to demand answers and prioritize patient lives over pharmaceutical patents.

Camus

11,864 görüntüleme • 11 ay önce

Dr. Aseem Malhotra exposes statins: A 1% benefit with hidden costs—time for informed consent Dr. Aseem Malhotra, a renowned cardiologist, has raised critical concerns about statins, one of the most prescribed drugs globally, with 30 million users in the U.S. and up to a billion worldwide. In a recent discussion, he unpacked the shocking truth about their efficacy, urging patients to question the widespread use of these cholesterol-lowering medications. Drawing from industry-sponsored trial data, Dr. Malhotra highlights that for most people—those not at high risk of heart attack—taking a statin daily for five years offers just a 1% chance of preventing a non-fatal heart attack or non-disabling stroke. Critically, this comes with no evidence of prolonging life by even a single day. He emphasizes that this information, available at is rarely communicated to patients due to systemic gaps in medical training, where doctors are not taught to interpret and convey such data effectively. Dr. Malhotra advocates for informed consent, presenting patients with these facts without coercion. Many, he notes, are dismayed by the minimal benefit when weighed against potential side effects, which affect 20-50% of users. These include muscle pain, fatigue, brain fog, erectile dysfunction, joint pain, and stomach issues. Strikingly, he has witnessed elderly patients misdiagnosed with dementia or frailty regain memory and vitality weeks after discontinuing statins. This is not a call to stop medication abruptly, but a plea for patients to engage in informed discussions with their doctors. Dr. Malhotra’s book, A Statin-Free Life, available on Amazon, delves deeper into these findings, offering a comprehensive resource for those seeking clarity on cholesterol management and drug benefits. For evidence-based insights on statins and other medications, visit Dr. Malhotra’s mission is clear: empower patients with knowledge to make health decisions that align with their values and quality of life.

Camus

107,694 görüntüleme • 1 yıl önce